Just three months after Nutcracker Therapeutics’ announcement of receiving $167 million in Series C funding, three new leadership positions have been filled alongside the release of its oncology and disease-focused pipeline. 22 June 2022
Privately-held contract research organization BioAgilytix Labs has announced the appointment of Euan Menzies as chairman and chief executive. 21 June 2022
Swiss antibody-drug conjugate specialist ADC Therapeutics announced today it has appointed industry veteran David Gilman to the new role of chief business and strategy officer, reporting to chief executive Ameet Mallik effective July 1. 13 June 2022
Biotech funder and incubator Flagship Pioneering and Tessera Therapeutics, a biotechnology company pioneering GENE WRITING technology backed by Flagship, today announced that Michael Severino has joined Tessera as chief executive. 3 June 2022
US biotech major Gilead Sciences has announced that Stacey Ma will join the company as executive vice president, pharmaceutical development and manufacturing, and will become a member of the company’s senior leadership team, reporting to chairman and chief executive, Daniel O’Day. 3 June 2022
London-headquartered generics company Hikma Pharmaceuticals has announced that its chief executive Siggi Olafsson has resigned in order to ‘pursue other opportunities’. 26 May 2022
An Expert View from Robert Wessman, chairman and CEO at global pharmaceutical company Alvogen, and founder and chairman at biopharma specialist, Alvotech. 25 May 2022
Privately-held Swiss drugmaker Helsinn Group has announced the appointment of Dr Melanie Rolli as group chief operating officer (COO), effective June 1, 2022. 19 May 2022
German firm Fresenius Kabi, a specialist in medicines and technologies for infusion, transfusion and clinical nutrition, has recruited Brandee Pappalardo as senior vice president and chief medical officer for North America. 19 May 2022
Gene therapy company Opus Genetics, which is developing treatments for inherited retinal diseases, today announced the appointment of Jennifer Hunt as chief development officer. 11 May 2022
US start-up biotech MOMA Therapeutics, which is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the completion of a $150 million Series B financing. 10 May 2022
Swiss antibody-drug conjugate specialist ADC Therapeutics today announced that Chris Martin has stepped down as chief executive of the company. 9 May 2022
Enthera Pharmaceuticals, a privately-held Italian biotech developing biologics for selected autoimmune conditions based on the discovery of an apoptosis pathway, has named Aled Williams chief executive. 6 May 2022
Coming out of stealth since its founding in 2019, US biotech Dianthus Therapeutics today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company. 3 May 2022
US messenger RNA (mRNA) therapeutics and vaccines specialist Moderna has announced that Arpa Garay will join the firm as chief commercial officer (CCO), effective Monday, May 31, 2022. She 28 April 2022
Boston, USA-based biotech start-up Jnana Therapeutics today announced the appointment of Doug Pagán, as both chief financial and chief operating officer. 26 April 2022
Privately-held French biotech focused on providing immuno-therapeutics Biomunex Pharmaceuticals today announces the appointment of Dr Simon Plyte as chief scientific officer (CSO) and as a member of its scientific advisory board. 25 April 2022
German drugmaker STADA Arzneimittel will from June add to its team by welcoming Dr Christine Berndt as head of global development Specialties/Biosimilars. 22 April 2022
Cancer-focused cell therapy company ImmPACT Bio USA today announced the appointment of Venkata Yepuri as chief operating officer. In this role, Mr Yepuri will oversee business operations across the company. 20 April 2022
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024